News

Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of the first two drugs to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…

Learn more about Idiopathic Pulmonary Fibrosis: http://bit.ly/1QiRmr3…

The Pulmonary Fibrosis Foundation (PFF) recently announced that the number of scientific poster presentations on idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILD) to be displayed at the upcoming PFF Summit 2015: From Bench to Bedside in Washington, D.C., reached a record. The PFF Summit 2015: From…

The Pulmonary Fibrosis Foundation (PFF) recently announced in a press release a five-year collaboration with Boehringer Ingelheim to support PFF programs dedicated to the improvement of the clinical outcome in patients with pulmonary fibrosis (PF), increase awareness about the disease, and offer advance care, disease education and…

The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role of Founding…

Esbriet is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Learn more: http://bit.ly/Esbriet Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This…

The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…

Boehringer Ingelheim Pharmaceuticals, Inc., recently announced data on the first 49 patients participating in the IPF-PRO (Idiopathic Pulmonary Fibrosis – PROspective Outcomes) Registry, better characterizing the features of patients with IPF when they are diagnosed with the disease. The data was presented at the American College of…

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…

Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…